Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Invested Capital (2021 - 2025)

Lyra Therapeutics has reported Invested Capital over the past 5 years, most recently at -$10.7 million for Q4 2025.

  • Quarterly results put Invested Capital at -$10.7 million for Q4 2025, down 192.44% from a year ago — trailing twelve months through Dec 2025 was -$10.7 million (down 192.44% YoY), and the annual figure for FY2025 was -$10.7 million, down 192.44%.
  • Invested Capital for Q4 2025 was -$10.7 million at Lyra Therapeutics, down from -$4.3 million in the prior quarter.
  • Over the last five years, Invested Capital for LYRA hit a ceiling of $106.2 million in Q2 2022 and a floor of -$10.7 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $52.3 million (2021), compared with a mean of $49.0 million.
  • Biggest five-year swings in Invested Capital: soared 184.18% in 2023 and later plummeted 192.44% in 2025.
  • Lyra Therapeutics' Invested Capital stood at $34.3 million in 2021, then soared by 135.32% to $80.8 million in 2022, then grew by 10.73% to $89.4 million in 2023, then tumbled by 87.03% to $11.6 million in 2024, then plummeted by 192.44% to -$10.7 million in 2025.
  • The last three reported values for Invested Capital were -$10.7 million (Q4 2025), -$4.3 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.